Ariel Beresniak, CEO of ATRA and Fleur Wesling, Mediacom Consulting

atra; setis rigidis numerosissimis obsita, alis opacis fuscis, capite brunneo.

Gillette Atra Plus Lubra Strip Cartridge - 10 ea

$17.99
  • Review
  • TAG : An escape to Atra is the best gift you could offer to a nature lover.
ADD TO CART
  • Aside from a few pieces of sports gear, my Gillette Atra razor handle is the only thing I’ve had for more than 10 years (I got it when I was 13). It’s made of solid, machined stainless steel and has a great classic look.

    ATRA was founded in 1986 by the American Council of Engineering Companies. Shortly thereafter, the American Medical Association joined them. Since that time, ATRA has been working to bring greater fairness, predictability and efficiency to America's civil justice system. Those efforts have resulted in the enactment of state and federal laws that make the system fairer for everyone. Further, ATRA is a nonpartisan, nonprofit organization with affiliated coalitions in more than 40 states. We are the only national organization dedicated exclusively to tort and liability reform through public education and the enactment of legislation. ATRA's membership is diverse and includes nonprofits, small and large companies, as well as state and national trade, business, and professional associations. Click for sample list of members.

  • The Advanced Transit Association (ATRA) is a non-profit organization aimed at increasing the knowledge and under- standing of innovative transit concepts. ATRA envisions a future when transportation will all be orchestrated for the convenience of people and their businesses – as well as for the benefit of our planet.

    ATRA is the only national organization exclusively dedicated to repairing our civil justice system. ATRA fights in Congress, in state legislatures, and in the courts to make the system fairer. We identify and champion elected officials and judges who want to fix the system. In the media, we serve as the national voice of the civil justice reform movement.

    Figure 1

    Nature Medicine  7, 662 - 664 (2001)
    doi:10.1038/89031
    Arthur Zelent
     
    Figure 1. Differentiation-inducing and apoptosis-inducing therapies for APL.
    APL can be treated (yellow arrows) with chemotherapy (CT), ATRA, combinations of ATRA and CT, or As2O3. ATRA induces differentiation and As2O3 primarily functions by inducing apoptosis. The effectiveness of these agents can be complicated by the emergence (orange arrows) of ATRA (APL-R) and As2O3 (APL-RS) resistant disease. TRAIL kills differentiated APL cells through a paracrine action (red arrow), suggesting that recombinant TRAIL (rTRAIL) might be used therapeutically (discontinuous blue arrows). TRAIL-mediated killing of APL cells might be enhanced by cotreatment with ATRA or As2O3. Altucci et al.1 suggest that concomitant treatment of cells with ATRA and TRAIL might provide a dominant death signal for APL cells before effective survival pathways are established. Past studies have also highlighted potential use of ATRA and HDACi (ref. 3) or RXR (rexinoid) and PKA agonists (cAMP)14, for treatment of ATRA and/or As2O3 resistant APL (purple arrow). It remains to be seen whether differentiation of APL cells induced by these drug combinations leads to TRAIL mediated cell death (?). Inset, survival pathways induced following ATRA treatment of APL cells. BCL2A1 and MCL1 are believed to have a role in both early and late anti-apoptotic programs. Late upregulation of cIAPs and TRAFS (mainly cIAP2 and TRAF1) as well as activation of NF-B suggests that these molecules contribute only to the second wave of anti-apoptotic activity. NF-B might also superinduce expression of its target gene BCL2A1 and act through cIAPs (cIAP2) to engage in establishment of signal amplification loop for cell survival (black arrows).

  • Figure 1

    Nature Medicine  7, 662 - 664 (2001)
    doi:10.1038/89031
    Arthur Zelent
     
    Figure 1. Differentiation-inducing and apoptosis-inducing therapies for APL.
    APL can be treated (yellow arrows) with chemotherapy (CT), ATRA, combinations of ATRA and CT, or As2O3. ATRA induces differentiation and As2O3 primarily functions by inducing apoptosis. The effectiveness of these agents can be complicated by the emergence (orange arrows) of ATRA (APL-R) and As2O3 (APL-RS) resistant disease. TRAIL kills differentiated APL cells through a paracrine action (red arrow), suggesting that recombinant TRAIL (rTRAIL) might be used therapeutically (discontinuous blue arrows). TRAIL-mediated killing of APL cells might be enhanced by cotreatment with ATRA or As2O3. Altucci et al.1 suggest that concomitant treatment of cells with ATRA and TRAIL might provide a dominant death signal for APL cells before effective survival pathways are established. Past studies have also highlighted potential use of ATRA and HDACi (ref. 3) or RXR (rexinoid) and PKA agonists (cAMP)14, for treatment of ATRA and/or As2O3 resistant APL (purple arrow). It remains to be seen whether differentiation of APL cells induced by these drug combinations leads to TRAIL mediated cell death (?). Inset, survival pathways induced following ATRA treatment of APL cells. BCL2A1 and MCL1 are believed to have a role in both early and late anti-apoptotic programs. Late upregulation of cIAPs and TRAFS (mainly cIAP2 and TRAF1) as well as activation of NF-B suggests that these molecules contribute only to the second wave of anti-apoptotic activity. NF-B might also superinduce expression of its target gene BCL2A1 and act through cIAPs (cIAP2) to engage in establishment of signal amplification loop for cell survival (black arrows).

    BlogIT is the Blog on Innovative Transit, as published on behalf of the ATRA Industry Group to allow ATRA IG to share its views on issues in the advanced transit industry.

= Meets ATRA's requirements. Bold = ATRA race member.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 8th. The company reported (Registration for the event is already open, and many well-known Badwater race veterans have already registered. These include Americans Bob Becker, Catra Corbett, Jimmy Dean Freeman, Charlie Engle, Jared Fetterolf, Joshua Holmes, Andrea Kooiman, and Ray Sanchez, plus Luigi Dessy of Puerto Rico, Carlo Sa of Portugal, Mick Thwaites of Australia, Dan Lawson of the United Kingdom, Mauro Chasilew of Brazil, Stacey Shand of Canada, and Hiroyuki Nishimura of Japan..66) earnings per share for the quarter, missing analysts’ consensus estimates of (Advanced transit networks have fully-automated operational capabilities that can often outperform conventional transit modes and complement our vehicle-highway system. They will typically have superior sustainability performance – social, economic and environmental – to all high-capacity alternatives. A wide range of concepts are embraced by ATRA in its vision to provide a sustainable transport network for the future..61) by .05. Equities analysts expect that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.